Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review.
Sunita PatruniFatima FayyazJeffrey Y BienTony PhilipDaniel A KingPublished in: JCO oncology practice (2022)
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human epidermal growth factor receptor 2 status, and PD-(L)1 expression on these guidelines. The role of immunotherapy in the locally advanced and metastatic setting is constantly expanding. Over the next few years, the many ongoing trials exploring immunotherapy are anticipated to bring new treatment regimens into the frontline setting with the potential to improve survival in patients with advanced disease.
Keyphrases
- epidermal growth factor receptor
- papillary thyroid
- clinical trial
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- squamous cell
- endothelial cells
- neoadjuvant chemotherapy
- tyrosine kinase
- advanced non small cell lung cancer
- machine learning
- combination therapy
- drug administration
- risk assessment
- electronic health record
- lymph node
- big data
- childhood cancer
- phase ii study